Having made its debut in the commercial market at the beginning of this year, Dexcom’s most recent continuous glucose monitor is making its way toward the end of 2023 by establishing a connection with Tandem Diabetes Care, which is the company’s first automated insulin pump partner.
As part of a synthetic pancreas system, the G7 continuous glucose monitor (CGM) from Dexcom will now be able to transmit its real-time readings of blood sugar to the t:slim X2 pump from Tandem. This will make it possible to automate the process of insulin administration and dosage calculations.
In the U.S., consumers who are currently utilizing the t:slim X2 can have access to the system by downloading a free software update. Additionally, new pumps will come with the integration already installed.
As stated by Dexcom, compliant G7 monitors are currently accessible via the company’s network of medical equipment distributors. The firm also intends to start distributing them within pharmacies in the country at the beginning of the new year. Additionally, the two want to extend the new link to a greater number of countries at the beginning of 2024.
Tandem CEO John Sheridan, celebrating the firm’s 10-year association with Dexcom, remarked, “With this launch we are offering more than 300,000 current t:slim X2 users the ability to integrate with Dexcom’s most advanced CGM technology, demonstrating our commitment to continued leadership in advancing AID systems.”
The G7, which was approved by the FDA a year ago, is supposed to be 60% smaller, provide a quicker sensor warming time, and make it simpler for users to switch out after its ten-day lifespan. The t:slim X2, which comes equipped with Control-IQ dosing software, was previously compatible with Dexcom’s G6 CGM.
At the beginning of this year, Tandem presented its ambitions for 2023, which included not only the integration of its pump with Dexcom’s G7, but also with Abbott’s FreeStyle Libre continuous glucose monitors. The objective was to make the t:slim X one of the first automatic insulin delivery systems that had been cleared by the FDA and could connect with several glucose sensor brands.
Tandem has stated that it will do “internal walkabout testing” prior to linking the systems, with the initial phase taking place in the U.S. and then spreading abroad. The procedure for Abbott’s FreeStyle Libre 2 has already begun, and the Libre 3 is scheduled to emerge not long after it has been completed.
Abbott has been collaborating with Tandem along with the associated pump creator Insulet with its Omnipod 5—as well as the MyLife Loop system, which was designed jointly with Ypsomed and the University of Cambridge spinout CamDiab and is now being pushed out across Europe. Abbott’s CGM sensors were granted approval by the FDA in March this year, enabling them to be utilized in automated insulin delivery systems.
